Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash & Current Investments: 2022-2025

Historic Cash & Current Investments for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to $7.7 million.

  • bioAffinity Technologies' Cash & Current Investments rose 862.50% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 45.21%. This contributed to the annual value of $1.1 million for FY2024, which is 60.83% down from last year.
  • Per bioAffinity Technologies' latest filing, its Cash & Current Investments stood at $7.7 million for Q3 2025, which was up 859.10% from $802,835 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Cash & Current Investments high stood at $13.5 million for Q3 2022, and its period low was $444,706 during Q1 2025.
  • For the 3-year period, bioAffinity Technologies' Cash & Current Investments averaged around $3.6 million, with its median value being $2.5 million (2024).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first slumped by 90.35% in 2024, then spiked by 862.50% in 2025.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' Cash & Current Investments stood at $11.4 million in 2022, then crashed by 75.28% to $2.8 million in 2023, then slumped by 60.83% to $1.1 million in 2024, then spiked by 862.50% to $7.7 million in 2025.
  • Its Cash & Current Investments was $7.7 million in Q3 2025, compared to $802,835 in Q2 2025 and $444,706 in Q1 2025.